title: [Miliary tuberculosis in a patient with morbus Bechterew treated with tumour necrosis factor-alpha].
abstract: Tumour necrosis factor (TNF)-α inhibitors are registered for treatment of several severe dermatologic, rheumatologic and gastrointestinal diseases. Due to TNF-α's important role in the immune system patients have increased risk of serious infections during treatment with TNF-α inhibitor. We here present a case of miliary tuberculosis complicated by pericardial effusion in a Danish man treated with TNF-α inhibitor that emphasizes the need for rapid examination of new symptoms in this patient category.
authors.affiliation: Medicinsk Afdeling, Roskilde Sygehus, Køgevej 7-13, 4000 Roskilde. casper@lund-andersen.com.
authors.forename: Casper
authors.initials: C
authors.lastname: Lund-Andersen
authors.forename: Mette
authors.initials: M
authors.lastname: Grove
authors.forename: Kirsten
authors.initials: K
authors.lastname: Rasmussen
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011859:Radiography; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014391:Tuberculosis, Miliary / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab